Pan-tumor MRD Study
Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers
- Muscle Invasive Bladder Urothelial Carcinoma
- Esophageal Cancer
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Melanoma (Skin Cancer)
- NSCLC (Non-small Cell Lung Cancer)
- Pancreatic (Exocrine Only)
- Mix of Solid Tumors (MOST)
At a glance
- Phase
- Phase not stated
- Study type
- Observational
- Sponsor
- Paradigm Health
- Enrolment target
- 1,350
- Started
- 8 January 2025
- Main results due
- December 2031
- Study sites
- 47
- Registry updated
- 24 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Eligibility Criteria:
1. Age 18 years or older.
2. Confirmed histological or cytological diagnosis of a malignant solid tumor that is either specified in one of the pre-defined tumor cohorts or meets the enrollment criteria for the Mix of Solid Tumors (MOST) cohort (Table 1).
3. Eligible for curative intent therapy, with surgical resection of cancer planned.
a. If surgical resection has occurred, enrollment should occur within 3 months of surgical resection and before initiation of adjuvant therapy.
4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2.
5. No systemic therapy for current cancer diagnosis administered before enrollment.
6. Willing and able to comply with required study procedures, including blood sample collection and primary tumor tissue submission from diagnostic biopsy or surgical excision.
7. Has completed all therapy (including endocrine therapy) 3 or more years ago for any previous invasive solid organ malignancy (with exception of nonmelanoma skin cancers) or hematologic malignancy. Individuals with a prior history of noninvasive (in situ) carcinomas may participate if they have received definitive treatment (no washout period required).
8. No concurrent diagnosis of another invasive cancer, except for nonmelanoma skin cancers.
9. No prior allogeneic hematopoietic stem cell transplant.
10. Able and willing to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for the release of personal health information.
Cohort Specific Criteria
11. Muscle-invasive urothelial carcinoma of the bladder and Melanoma Cohorts: Stage II or operable III cancer:
12. Esophageal, Gastric/GEJ, and NSCLC Cohorts: Stage I, II, or operable III cancer.
13. Pancreatic Cohort: Stage I, II or operable III cancer, exocrine only disease.
14. MOST cohort: Stage II or operable stage III solid tumor diagnosis that meets eligibility criteria and is not included in the other cohorts.
The following tumor types are excluded:
1. Central nervous system (CNS) malignancies
2. Colorectal cancer
3. Breast cancer
4. Squamous cell skin cancer
5. Basal cell carcinoma
6. Gastrointestinal stromal tumors (GIST)
7. Thyroid cancer
8. Uveal melanoma
9. Low or intermediate grade neuroendocrine tumors
■ Eligible tumor types: High-grade neuroendocrine tumors, including neuroendocrine carcinomas, Merkel cell carcinomas, and small cell lung cancer are permissible
10. Hematologic cancers including multiple myeloma or other plasma cell dyscrasias, Hodgkin\'s lymphoma, non-Hodgkin\'s lymphoma, acute or chronic leukemias including chronic lymphocytic leukemia / small lymphocytic leukemiaWhat this study is about
In the sponsor’s own words, from the registry.
The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back.
Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.
Study sites(47)
Alabama Oncology
Birmingham, Alabama, United States
Recruiting
Mohtaseb Cancer Center and Blood Disorders
Bullhead City, Arizona, United States
Recruiting
Cancer & Blood Specialists of Arizona
Casa Grande, Arizona, United States
Recruiting
CARTI
Little Rock, Arkansas, United States
Recruiting
Highlands Oncology Group (HOG)
Springdale, Arkansas, United States
Recruiting
Los Angeles Cancer Network (LACN)
Glendale, California, United States
Recruiting
Ventura County Hematology Oncology Specialists
Oxnard, California, United States
Recruiting
Medical Oncology Associates of San Diego (MOASD)
San Diego, California, United States
Recruiting
Medical Oncology Associates of San Diego
San Diego, California, United States
Recruiting
Stockton Hematology Oncology Med Group
Stockton, California, United States
Recruiting
The Melanoma and Skin Cancer Institute
Englewood, Colorado, United States
Recruiting
Oncology & Hematology Associates of West Broward
Coral Springs, Florida, United States
Recruiting
Mid Florida Cancer Centers
Orange City, Florida, United States
Recruiting
Comprehensive Hematology Oncology (CHO)
St. Petersburg, Florida, United States
Recruiting
Piedmont Cancer Institute
Atlanta, Georgia, United States
Recruiting
Cancer Care Specialists of Illinois (CCSI)
O'Fallon, Illinois, United States
Recruiting
Carle Health
Urbana, Illinois, United States
Recruiting
Cotton O'Neil Cancer Center [Stormont Vail]
Topeka, Kansas, United States
Recruiting
Cancer Center of Kansas
Wichita, Kansas, United States
Recruiting
Baptist Health Corbin
Corbin, Kentucky, United States
Recruiting
Baptist Health Hardin
Elizabethtown, Kentucky, United States
Recruiting
Baptist Health Lexington
Lexington, Kentucky, United States
Recruiting
Baptist Health Louisville
Louisville, Kentucky, United States
Recruiting
Pontchartrain Cancer Center
Covington, Louisiana, United States
Recruiting
Christus Health Highlands
Shreveport, Louisiana, United States
Recruiting
The Cancer & Hematology Centers (CHC)
Grand Rapids, Michigan, United States
Recruiting
Mayo Clinic
Rochester, Minnesota, United States
Recruiting
Cox Health
Springfield, Missouri, United States
Recruiting
Cancer Partners of Nebraska
Lincoln, Nebraska, United States
Recruiting
San Juan Oncology Associates
Farmington, New Mexico, United States
Recruiting
Guthrie Lourdes Memorial Hospital (GLMH)
Binghamton, New York, United States
Recruiting
New York Cancer & Blood Specialists
Shirley, New York, United States
Recruiting
Carolina Oncology Specialists
Charlotte, North Carolina, United States
Recruiting
Southeastern Medical Oncology Center (SMOC)
Goldsboro, North Carolina, United States
Recruiting
Regional Medical Oncology Center
Wilson, North Carolina, United States
Recruiting
Gabrail Cancer Center
Canton, Ohio, United States
Recruiting
Taylor Cancer Research Center
Maumee, Ohio, United States
Recruiting
Oklahoma Cancer Specialists and Research Institute (OCSRI)
Tulsa, Oklahoma, United States
Recruiting
Oregon Health & Science University (OHSU)
Portland, Oregon, United States
Recruiting
Lancaster General Hospital (UPenn)
Lancaster, Pennsylvania, United States
Recruiting
Guthrie Foundation
Sayre, Pennsylvania, United States
Recruiting
Cancer Care Associates of York (CCAY)
York, Pennsylvania, United States
Recruiting
Onocology Consultants P.A. (Oncology Consultants [OC Houston])
Houston, Texas, United States
Recruiting
Community Clinical Trials
Kingwood, Texas, United States
Recruiting
Christus St. Michael's
Texarkana, Texas, United States
Recruiting
Virginia Cancer Institute
Richmond, Virginia, United States
Recruiting
Northwest Medical Specialties (NWMS)
Tacoma, Washington, United States
Recruiting
Showing 47 of 47 sites. 47 of the 47 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT06605404. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me